Drug Database · Clinicians

Amlodipine + Perindopril

Brands (4) Amloperi, Coveram, Viacoram…Show all

ACE inhibitor and calcium channel blocker; Antihypertensive/Anti-Coronary artery disease (CAD); and others PH FDA category
Fixed-dose combination.

Not suitable if CrCl <60: use componentsRx · Prescription drug10 PH productsVAT-exempt Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Contraindications

  • History of ACE-inhibitor angioedema; hereditary or idiopathic angioedema
  • Second and third trimesters of pregnancy
  • Significant bilateral renal artery stenosis or stenosis to a single functioning kidney
  • Aliskiren with diabetes or GFR <60 mL/min/1.73 m2
  • Sacubitril/valsartan within 36 hours
  • Extracorporeal treatments using negatively charged surfaces (some high-flux membranes, LDL apheresis)
  • Severe hypotension, shock, left ventricular outflow obstruction
  • Hemodynamically unstable heart failure after acute myocardial infarction
  • Hypersensitivity to perindopril, other ACE inhibitors or dihydropyridines
renalcarematters.com, reviewed

Dosing: Adult

  • Hypertension or stable coronary artery disease, substitution for the separate drugs: One tablet once daily in the morning before a meal, at the same perindopril and amlodipine doses the patient already takes
renalcarematters.com, reviewed

Dosing: Altered kidney function

The fixed combination is a substitution product for patients already controlled on the same doses given separately. Perindoprilat, the active ACE-inhibitor metabolite, is cleared by the kidneys and accumulates in kidney impairment, whereas amlodipine needs no kidney adjustment. The European label allows the combination only at creatinine clearance (CrCl) 60 mL/min or above; below that, the components are titrated separately. It has no US FDA label.

Kidney function measure: European summary of product characteristics (SmPC) uses creatinine clearance (CrCl, mL/min).

Show full dosing details
CrCl ≥60 mL/min
One tablet once daily in the morning before a meal, at the strengths the patient already takes as separate drugs (SmPC). Monitor potassium and creatinine.
CrCl 30–59 mL/min
Not suitable at CrCl <60 mL/min: titrate perindopril and amlodipine separately (SmPC). Perindoprilat accumulates as kidney function falls.
CrCl 15–29 mL/min
Not suitable at CrCl <60 mL/min: titrate perindopril and amlodipine separately (SmPC). Perindoprilat accumulates as kidney function falls.
CrCl <15 mL/min (not on dialysis)
Not suitable at CrCl <60 mL/min: titrate perindopril and amlodipine separately (SmPC). Perindoprilat accumulates as kidney function falls.
Hemodialysis (intermittent)
Not suitable (CrCl <60). Perindoprilat is dialyzable (dialysis clearance 70 mL/min); amlodipine is not. Use the separate drugs. Avoid high-flux polyacrylonitrile (AN69) membranes with ACE inhibitors (anaphylactoid reactions) (SmPC 4.3, 4.4).
Peritoneal dialysis
Not suitable (CrCl <60); use the separate drugs.
CRRT
Not suitable; use separate drugs if needed. Extracorporeal circuits with negatively charged surfaces are contraindicated with ACE inhibitors (SmPC 4.3).
  • Dialyzable? Perindoprilat: yes (dialysis clearance 70 mL/min). Amlodipine: no (about 97.5% protein-bound) (SmPC).
  • Monitoring Potassium and creatinine routinely in CKD; blood pressure, kidney function and potassium closely in patients at risk of hypotension or with renal artery stenosis. Hyperkalemia risk higher with CKD, age over 70, diabetes, potassium-sparing diuretics, potassium supplements or salt substitutes (SmPC 4.4).
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: HPRA (Ireland) product information (August 2022). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Not established in children (SmPC).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Tablet: 3.5 mg/2.5 mg, 5 mg/10 mg, 5 mg/5 mg, 7 mg/5 mg, 10 mg/10 mg, 10 mg/5 mg

Registered products in the Philippines

10 products registered with the Food and Drug Administration (FDA) Philippines list Amlodipine + Perindopril as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products10
Philippine FDA-registered products for Amlodipine + Perindopril
Package insert
AmloperiPerindopril (as arginine) + Amlodipine (as besilate)
10 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc.
DRP-17664
Mar 12, 2032
AmloperiPerindopril (As Arginine) + Amlodipine (As Besilate)
3.5mg/2.5mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises, Inc.
DRP-18360
Jun 23, 2032
AmloperiPerindopril (as arginine) + Amlodipine (as besilate)
5 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc.
DRP-17666
Mar 12, 2032
AmloperiPerindopril (as arginine) + Amlodipine (as besilate)
7 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc.
DRP-17665
Mar 12, 2032
CoveramPerindopril (as arginine) + Amlodipine (as besilate)
10 mg/ 5 mg TabletPolypropylene Bottle x 30's (Box of 1's)
RxVAT-exempt
Servier (Ireland) Industries Ltd.Ireland
Zuellig Pharma CorporationImporter: Servier Philippines, Inc.
DR-XY36011
Jun 22, 2029
CoveramPerindopril (as arginine) + Amlodipine (as besilate)
10 mg/10 mg TabletPolypropylene Bottle x 30's Box of 1's
RxVAT-exempt
Servier (Ireland) Industries Ltd.Ireland
Zuellig Pharma CorporationImporter: Servier Philippines, Inc.
DR-XY36012
Jun 22, 2029
CoveramPerindopril (as arginine) + Amlodipine (as besilate)
5 mg/ 10 mg TabletPolypropylene Bottle x 30's Box of 1's
RxVAT-exempt
Servier (Ireland) Industries Ltd.Ireland
Zuellig Pharma CorporationImporter: Servier Philippines, Inc.
DR-XY36010
Jun 22, 2029
CoveramPerindopril (as arginine) + Amlodipine (as besilate)
5 mg/5 mg TabletPolypropylene Bottle x 30's Box of 1's
RxVAT-exempt
Servier (Ireland) Industries Ltd.Ireland
Zuellig Pharma CorporationImporter: Servier Philippines, Inc.
DR-XY36009
Jun 22, 2029
ViacoramPerindopril (as arginine) + Amlodipine (as besilate)
7 mg/ 5mg TabletPolypropylene container x 30's (Box of 1's)
RxVAT-exempt
Servier (Ireland) Industries, Ltd.Ireland
Zuellig Pharma CorporationImporter: Servier Philippines, Inc.Trader: Les Laboratoires Servier
DR-XY45453
Jun 20, 2031
Viacoram InitioPerindopril (as arginine) + Amlodipine (as besilate)
3.5 mg/ 2.5 mg TabletPolypropylene container x 30's (Box of 1's)
RxVAT-exempt
Servier (Ireland) Industries, Ltd.Ireland
Zuellig Pharma CorporationImporter: Servier Philippines, Inc.Trader: Les Laboratories Servier
DR-XY45452
Jun 20, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
AliskirenAvoidHyperkalemia, kidney impairment, hypotension.Contraindicated with diabetes or GFR <60; otherwise not recommended.
Sacubitril/valsartanAvoidAngioedema.Contraindicated; separate by 36 hours.
ARBs (dual RAAS blockade)AvoidHyperkalemia, acute kidney injury, hypotension.Not recommended; specialist only with close monitoring.
Potassium-sparing diuretics, potassium supplements, salt substitutesAdjust or monitorHyperkalemia.Not recommended; if needed, monitor potassium frequently.
NSAIDsAdjust or monitorLess blood-pressure control; kidney injury and hyperkalemia.Hydrate; monitor kidney function.
LithiumAdjust or monitorLithium toxicity.Not recommended; monitor lithium levels if needed.
Strong or moderate CYP3A4 inhibitors; tacrolimus, cyclosporine; simvastatinAdjust or monitorHigher amlodipine exposure; amlodipine raises tacrolimus and cyclosporine levels and simvastatin exposure.Monitor; check immunosuppressant levels; limit simvastatin to 20 mg/day.
Racecadotril, mTOR inhibitors, gliptinsAdjust or monitorHigher angioedema risk.Caution when starting.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Edema (amlodipine)
  • Cough (perindopril)
  • Dizziness, headache, hypotension
  • Palpitations, flushing
  • Gastrointestinal upset

Serious

  • Angioedema
  • Hyperkalemia
  • Acute kidney injury (especially with renal artery stenosis, volume depletion, NSAIDs)
  • Agranulocytosis, thrombocytopenia (very rare)
renalcarematters.com, reviewed

Monitoring parameters

  • Potassium and creatinine routinely in CKD; blood pressure, kidney function and potassium closely in patients at risk of hypotension or with renal artery stenosis. Hyperkalemia risk higher with CKD, age over 70, diabetes, potassium-sparing diuretics, potassium supplements or salt substitutes (SmPC 4.4). Kidney
  • Potassium and creatinine (within 1 to 2 weeks of starting or changing dose, then periodically)
  • Blood pressure
  • Angioedema symptoms
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Half-lifePerindoprilat about 17 hours (unbound terminal); amlodipine 35 to 50 hours
Half-life in kidney failure (ESKD) kidneyPerindoprilat elimination reduced in kidney failure (not quantified); amlodipine unchanged
Protein bindingPerindoprilat 20%; amlodipine about 97.5%
Metabolism (CYP, transporters)Perindopril hydrolyzed to active perindoprilat; amlodipine hepatic (CYP3A4)
Active metabolitesPerindoprilat
Renal excretion kidneyPerindoprilat in urine; amlodipine 10% unchanged and 60% as metabolites in urine
Dialyzability kidneyPerindoprilat yes (70 mL/min); amlodipine no
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Health Products Regulatory Authority (Ireland). Acerycal 5 mg/5 mg tablets SmPC (PA0568/018/001) [HPRA (Ireland) product information, August 2022; no US FDA label]. https://assets.hpra.ie/products/Human/18541/Licence_PA0568-018-001_08082022103112.pdf
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Les Laboratoires Servier. (2022). Acerycal 5 mg/5 mg tablets (perindopril arginine/amlodipine) [Summary of product characteristics, licence PA0568/018/001; text revised August 2022]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/18541/Licence_PA0568-018-001_08082022103112.pdf

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .